As part of the organizational changes, Dr.
Dr. Gupta said, "I have been incredibly fortunate to be involved in
Senior Leadership Team Changes and Appointments
Wes Kaupinen, who has served as Vice President of Corporate Development and Commercialization since he joined Insmedin August 2013, will now report directly to Mr. Lewis. Mr. Kaupinenis focused on identifying commercial stage and other opportunities that strengthen the future growth profile of Insmedin orphan, pulmonary and infectious diseases.
John Gollhas joined as Vice President, Corporate Controller, reporting to Andy Drechsler, Chief Financial Officer. Mr. Gollbrings over 20 years of senior-level financial and accounting experience in the global pharmaceutical industry, including at multi-product, revenue-generating companies. Previously, Mr. Gollworked at Warner Chilcott plc, a publicly traded global specialty pharmaceuticals company (acquired by Actavis plc in October 2013) where he was Vice President, Corporate Controller.
Drayton Wisehas joined as Senior Director of Commercial Operations reporting to Matthew Pauls, Chief Commercial Officer. He will focus on the design and build-out of key parts of the Company's commercial infrastructure. Previously, Mr. Wiseworked at Novartis, where he led the U.S. sales launch of the TOBI Podhaler, Novartis' leading product for the treatment of CF.
Jill Dolginhas joined as Senior Director of Patient Advocacy and Public Policy, reporting to Mr. Pauls. With over 14 years of experience in patient advocacy, she will be responsible for developing relationships with advocates, professional organizations, policy makers, and for building a patient advocacy and policy team. Most recently, Ms. Dolgin worked at Onyx Pharmaceuticalswhere she built the advocacy and professional affairs function.
Kevin McDermotthas joined as Head of Global Market Access, reporting to Mr. Pauls. He will be responsible for building a global market access team, developing pricing strategies, creating a strong pharmacoeconomic foundation, and securing market access. Mr. McDermotthas over 14 years of senior leadership in market access, and he most recently directed the Managed Markets team at Aptalis Pharmaceuticals.
Kevin Schutzhas joined as Senior Director, Regulatory Affairs, reporting to Peggy Berry, Vice President of Regulatory Affairs. Most recently, Mr. Schutzworked at Antares Pharma, where he focused on regulatory strategy for the launch of their first self-commercialized product. He was previously Director of Regulatory Affairs at Amarin Corporation, where he led the company's preparation and response to the U.S. Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee.
"I am confident we are building an executive team with the breadth and depth of expertise and experience needed to accomplish our ambitious goal of creating a best-in-class biopharmaceutical company," said
This release contains forward-looking statements. Words, and variations of words, such as "intend," "expect," "will," "anticipate," "believe," "continue," "propose" and similar expressions are intended to identify forward-looking statements. Investors are cautioned that such statements in this release, including statements relating to the status, results and timing of clinical trials and clinical data, the anticipated benefits of